We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Anticancer Therapies – Products

Cancer cells.
Product News

Estonia Develops Personalized CAR-T Cell Therapy for Blood Cancer Patients

The Tartu University Hospital, North Estonia Medical Centre, and Icosagen have joined forces to develop and introduce an innovative personalized cell therapy (CAR-T cell therapy) for patients in Estonia.
CD2-CD58 Axis: Targets in Immune Synapse, cancer immunotherapy, autoimmune diseases, immune evasion of tumors, antiviral responses, immune rejection

CD2-CD58 Axis: Targets in Immune Synapse

Sino Biological offers a wide range of recombinant CD2 and CD58 proteins and antibodies to support elucidating key interactions and pathways and shedding light on potential therapeutic strategies.
Cancer cells.
Product News

OncoHost To Present Poster Demonstrating PROphet®’s Application in Multiple Cancer Indications at ASCO 2024

Plasma-based proteomic platform predicts clinical benefit from immune-checkpoint inhibitors in NSCLC, melanoma, and HPV-related cancers.
Five blood bags.
Product News

Thermo Fisher Scientific Introduces Array-Based Solution for Extended Blood Type Research

The Applied Biosystems™ Axiom™ BloodGenomiX™ Array and Software provide a high-throughput solution for more precise blood matching research.
Cancer cells under a microscope, showing abnormal growth and division.
App Note / Case Study

A Rapid and Robust Solution for Cellular Response Characterization

This app note explores the use of an assay to facilitate rapid monitoring of T-cell function and simultaneous assessment of cell phenotype, activation markers, proliferation, viability and cytokine secretion.
A labelled antibody and a cell.
Product News

FDA-Approved TIVDAK®: Targeting Tissue Factor in Cervical Cancer

On April 29th, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment of patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.
Product News

Thermo Fisher Scientific Introduces Animal Origin-Free Formulation To Support Scaling of Cell Therapy Manufacturing

Breakthrough medium delivers speed and scale to CAR-T cell therapy manufacturers.
Double helix structure of DNA.
Product News

University of Liverpool To Use Touchlight’s Rapid Enzymatic dbDNA in Fully Personalised Neoantigen Cancer Vaccine Clinical

The UK’s Medical Research Council is funding a 10-patient Phase I study to deliver rapid personalised treatment for lung cancer patients.
Product News

Therapeutic Potential of CD20 X CD3 Bispecific Antibodies

As of March 2024, the FDA has approved three CD20 × CD3 BsAbs: mosunetuzumab (Lunsumio) for relapsed or refractory follicular lymphoma (R/R FL), glofitamab (Columvi) for relapsed or refractory diffuse B cell lymphoma
Cancer immunotherapy cells

Cancer Immunotherapies: The Paths From Models to Treatments

In this compendium, Technology Networks presents a collection of handpicked resources, including infographics, listicles, an article and webinar, that will help you to learn more about the latest advancements with disease modeling and cancer immunotherapies.